Bioactivity | H3B-8800 is a potent and orally active SF3B splicing modulator. H3B-8800 direct interaction with the SF3b complex and shows anti-cancer activity. H3B-8800 has the potential for the research of acute myeloid leukemia (AML) with SF3B1 mutant[1]. | |||||||||
Target | SF3B splicing | |||||||||
Invitro | H3B-8800 (0.1-10000 nM; 72 h)抑制 SF3B1 突变细胞系 Panc05.04 细胞的生长[1]。H3B-8800 (0.1-10000 nM; 24 h) 以剂量依赖性方式诱导 SF3B1 突变细胞系 Panc05.04 细胞凋亡[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> H3B-8800 相关抗体: Apoptosis Analysis[1] Cell Line: | |||||||||
In Vivo | H3B-8800 (2, 4 mg/kg; p.o.; daily) 在具有 SF3B1 突变的 AML 衍生异种移植物 (PDX) 模型中显示出抗肿瘤活性[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: | |||||||||
CAS | 1825302-42-8 | |||||||||
Formula | C31H45N3O6 | |||||||||
Molar Mass | 555.71 | |||||||||
Appearance | 固体 | |||||||||
Transport | Room temperature in continental US; may vary elsewhere. | |||||||||
Storage |
|
|||||||||
Reference | [1]. Seiler M, et al. H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers. Nat Med. 2018 May;24(4):497-504. |